Alprolix
Total Payments
$529,713
Transactions
419
Doctors
87
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $5,288 | 2 | 1 |
| 2018 | $168,907 | 139 | 17 |
| 2017 | $355,518 | 278 | 76 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $431,235 | 233 | 81.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $83,269 | 18 | 15.7% |
| Travel and Lodging | $5,785 | 21 | 1.1% |
| Consulting Fee | $5,288 | 2 | 1.0% |
| Food and Beverage | $3,412 | 119 | 0.6% |
| Education | $723.81 | 26 | 0.1% |
Payments by Type
Research
$431,235
233 transactions
General
$98,477
186 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Natural History Study of Factor IX Treatment and Complications (B-Natural) | Swedish Orphan Biovitrum AB | $191,316 | 0 |
| Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B | Bioverativ Therapeutics Inc. | $140,863 | 0 |
| EHL Products for Heavy Menstrual Bleeding in Hemophilia Carriers | Bioverativ Therapeutics Inc. | $42,541 | 0 |
| Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B | Bioverativ Therapeutics Inc. | $28,780 | 0 |
| U of U PORC SRA US-FAB-16-10971 AOP16-64 | Bioverativ Therapeutics Inc. | $27,735 | 0 |
Top Doctors Receiving Payments for Alprolix
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cincinnati, OH | $464,669 | 240 |
| , M.D., M.P.H | Pediatric Hematology-Oncology | Loxahatchee, FL | $20,935 | 17 |
| , M.D., PHD | Hematology & Oncology | Sacramento, CA | $10,382 | 9 |
| , M.D | Hematology | Los Angeles, CA | $10,152 | 7 |
| , M.D | Internal Medicine | Memphis, TN | $7,829 | 9 |
| , MD | Pediatric Hematology-Oncology | Atlanta, GA | $5,288 | 2 |
| , MD | Pediatric Hematology-Oncology | Miami, FL | $3,874 | 5 |
| , MD, MPH | Pediatrics | Pittsburgh, PA | $2,120 | 1 |
| , MD | Hematology & Oncology | Chapel Hill, NC | $598.07 | 4 |
| , MO | Pediatric Hematology-Oncology | Pacheco, CA | $492.90 | 4 |
| , MD | Pediatric Hematology-Oncology | Pacheco, CA | $434.57 | 3 |
| , MD | Hematology & Oncology | New York, NY | $153.11 | 4 |
| , MD, PHD | Medical Oncology | Portland, OR | $144.54 | 3 |
| , M.D | Internal Medicine | Salt Lake City, UT | $125.07 | 2 |
| , MD | Hematology & Oncology | Scarborough, ME | $119.53 | 3 |
| , MBBS | Pediatric Hematology-Oncology | Scarborough, ME | $111.16 | 1 |
| , MD | Hematology | Honolulu, HI | $100.20 | 1 |
| , MD | Internal Medicine | Honolulu, HI | $100.20 | 1 |
| Paul Swerdlow | — | Farmington Hills, MI | $83.33 | 1 |
| , MD | Hematology | Newark, DE | $81.42 | 6 |
| , MD | Pulmonary Disease | Los Angeles, CA | $73.27 | 1 |
| , D.O | Pediatric Hematology-Oncology | Tampa, FL | $68.72 | 2 |
| , MD | Hematology | Newark, DE | $64.31 | 6 |
| , MD | Hematology | Newark, DE | $57.88 | 5 |
| , M.D | Pediatric Hematology-Oncology | Madera, CA | $55.91 | 3 |
Ad
Manufacturing Companies
- Bioverativ Therapeutics Inc. $333,109
- Swedish Orphan Biovitrum AB $191,316
- SWEDISH ORPHAN BIOVITRUM AB $5,288
Product Information
- Type Drug
- Total Payments $529,713
- Total Doctors 87
- Transactions 419
About Alprolix
Alprolix is a drug associated with $529,713 in payments to 87 healthcare providers, recorded across 419 transactions in the CMS Open Payments database. The primary manufacturer is Bioverativ Therapeutics Inc..
Payment data is available from 2017 to 2022. In 2022, $5,288 was paid across 2 transactions to 1 doctors.
The most common payment nature for Alprolix is "Unspecified" ($431,235, 81.4% of total).
Alprolix is associated with 5 research studies, including "Natural History Study of Factor IX Treatment and Complications (B-Natural)" ($191,316).